Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Net Cash Flow (2016 - 2025)

Syndax Pharmaceuticals has reported Net Cash Flow over the past 11 years, most recently at $18.0 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $18.0 million for Q4 2025, down 14.51% from a year ago — trailing twelve months through Dec 2025 was -$19.3 million (up 86.36% YoY), and the annual figure for FY2025 was -$19.3 million, up 86.36%.
  • Net Cash Flow for Q4 2025 was $18.0 million at Syndax Pharmaceuticals, up from $8.2 million in the prior quarter.
  • Over the last five years, Net Cash Flow for SNDX hit a ceiling of $200.8 million in Q4 2023 and a floor of -$180.8 million in Q1 2024.
  • Median Net Cash Flow over the past 5 years was $1.4 million (2022), compared with a mean of $983700.0.
  • Biggest five-year swings in Net Cash Flow: plummeted 1975.08% in 2022 and later skyrocketed 6641.99% in 2023.
  • Syndax Pharmaceuticals' Net Cash Flow stood at $150.5 million in 2021, then crashed by 98.02% to $3.0 million in 2022, then skyrocketed by 6641.99% to $200.8 million in 2023, then tumbled by 89.51% to $21.1 million in 2024, then dropped by 14.51% to $18.0 million in 2025.
  • The last three reported values for Net Cash Flow were $18.0 million (Q4 2025), $8.2 million (Q3 2025), and -$45.4 million (Q2 2025) per Business Quant data.